Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 15/20 | 0.54 |
| ▸ | NPY1R | P25929 | 10/20 | 0.54 |
| ▸ | NPY5R | Q15761 | 9/20 | 0.54 |
| ▸ | NPY2R | P49146 | 6/20 | 0.54 |
| ▸ | CHRND | Q07001 | 4/20 | 0.48 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.48 |
| ▸ | CHRNG | P07510 | 1/20 | 0.48 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15092953 | 1.00 | NPY4R (0.54) | NPY4RNPY1RNPY5RNPY2RCHRND | |
| SCHEMBL21481072 | 0.93 | NPY4R (0.59) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL29391074 | 0.93 | NPY4R (0.59) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL30090470 | 0.91 | NPY4R (0.62) | NPY4RNPY1RNPY5RNPY2RCHRND | |
| SCHEMBL31261768 | 0.91 | NPY4R (0.57) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL9522231 | 0.91 | NPY4R (0.51) | NPY4RNPY1RNPY5RNPY2RCHRND | |
| SCHEMBL18970523 | 0.91 | NPY4R (0.58) | NPY4RNPY1RNPY5RNPY2RCHRND | |
| SCHEMBL29794248 | 0.90 | NPY4R (0.56) | NPY4RNPY1RNPY5RNPY2RCHRND | |
| SCHEMBL31019151 | 0.90 | NPY4R (0.59) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL30495709 | 0.89 | NPY4R (0.52) | NPY4RNPY1RNPY5RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3309171-B1 | BLOOD-BRAIN BARRIER PERMEABLE PEPTIDE COMPOSITIONS | ICB INT INC (US) | 2021-06-09 | — | — | EP | disclosed |
| US-20210017262-A1 | BLOOD-BRAIN BARRIER PERMEABLE PEPTIDE COMPOSITIONS | ICB INT INC (US) | 2021-01-21 | — | — | US | disclosed |
| US-10738109-B2 | Blood-brain barrier permeable peptide compositions comprising a VAB domain of an anti-amyloid-beta camelid single-domain heavy-chain only antibody | ICB INTERNATIONAL, INC. (US) | 2020-08-11 | — | — | US | disclosed |
| EP-2754670-B1 | BLOOD-BRAIN BARRIER PERMEABLE PEPTIDE COMPOSITIONS | ICB INT INC (US) | 2019-05-22 | — | — | EP | disclosed |
| US-20190002544-A1 | BLOOD-BRAIN BARRIER PERMEABLE PEPTIDE COMPOSITIONS | ICB INTERNATIONAL, INC. | 2019-01-03 | — | — | US | disclosed |
| US-10112988-B2 | Methods of assessing amyloid-beta peptides in the central nervous system by blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an anti-amyloid-beta peptide | ICB INTERNATIONAL, INC. (US) | 2018-10-30 | — | — | US | disclosed |
| US-10112987-B2 | Blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an amyloid-beta peptide | ICB INTERNATIONAL, INC. (US) | 2018-10-30 | — | — | US | disclosed |
| EP-3309171-A1 | BLOOD-BRAIN BARRIER PERMEABLE PEPTIDE COMPOSITIONS | ICB International, Inc. (US) | 2018-04-18 | — | — | EP | disclosed |
| EP-2664625-B1 | Blood-brain barrier permeable peptide compositions | ICB INT INC (US) | 2017-08-23 | — | — | EP | disclosed |
| US-20140193834-A1 | BLOOD-BRAIN BARRIER PERMEABLE PEPTIDE COMPOSITIONS | ICB INTERNATIONAL, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| EP-2664625-A2 | Blood-brain barrier permeable peptide compositions | ICB International, Inc. (US) | 2013-11-20 | — | — | EP | disclosed |
| US-20130177568-A1 | BLOOD-BRAIN BARRIER PERMEABLE PEPTIDE COMPOSITIONS | ICB INTERNATIONAL, INC. (US) | 2013-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210017262-A1 | BLOOD-BRAIN BARRIER PERMEABLE PEPTIDE COMPOSITIONS | FCGR2A, VSIR, FCGR3B | NPY4R 620/4885NPY1R 147/4885NPY5R 437/4885 |
| US-10112988-B2 | Methods of assessing amyloid-beta peptides in the central nervous system by blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an anti-amyloid-beta peptide | VSIR, APP, FCGR2A | NPY4R 1139/4885NPY1R 442/4885NPY5R 695/4885 |
| US-10738109-B2 | Blood-brain barrier permeable peptide compositions comprising a VAB domain of an anti-amyloid-beta camelid single-domain heavy-chain only antibody | VSIR, APP, ATP6V1B2 | NPY4R 1653/4885NPY1R 669/4885NPY5R 979/4885 |
| US-10112987-B2 | Blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an amyloid-beta peptide | VSIR, APP, ATP6V1B2 | NPY4R 1446/4885NPY1R 680/4885NPY5R 1025/4885 |
| US-20130177568-A1 | BLOOD-BRAIN BARRIER PERMEABLE PEPTIDE COMPOSITIONS | FCGR2A, VSIR, FCGR3B | NPY4R 620/4885NPY1R 147/4885NPY5R 437/4885 |
| US-20190002544-A1 | BLOOD-BRAIN BARRIER PERMEABLE PEPTIDE COMPOSITIONS | FCGR2A, VSIR, FCGR3B | NPY4R 620/4885NPY1R 147/4885NPY5R 437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.